Valeant agrees to acquire Sanofi's dermatology unit for $425M
This article was originally published in Scrip
Canadian company Valeant Pharmaceuticals International has agreed to buy Sanofi's dermatology unit Dermik for $425 million in cash. Dermik has a significant presence in the dermatology market in both the US and Canada. Along with a portfolio of products to boost its growing dermatology business, Valeant is set to gain Sanofi's Laval, Canada manufacturing facility.